Connect with us

Covid-19

Pfizer close to big step toward youngsters vaccine

Published

on

Salt Lake City, Utah – According to Pfizer’s CEO “it’s a question of days, not weeks” before the company and German partner BioNTech submit data to U.S. regulators for federal authorization of a COVID-19 vaccine for children age 5 to 11.

Now, when kids are back in school and the delta variant resulting in a big jump in pediatric infections, that would be an important step toward starting vaccinations for youngsters.

Last week Pfizer said that its vaccine is already available for anyone 12 and older. The company said that after children age 5 to 11 got their second dose during testing, they developed coronavirus-fighting antibody levels just as strong as teenagers and young adults getting the regular-strength shots.

According to Pfizer CEO Albert Bourla, if the Food and Drug Administration approves the company’s application, they will be ready with their manufacturing to provide this new formulation of the vaccine.

Bourla said, “This Week” that within a year, “I think we will be able to come back to normal life. I don’t think that this means that variants will not be continuing coming. And I don’t think that this means that we should be able to live our lives without having vaccinations, basically.”

Bourla also said “we will have vaccines that will last at least a year’’ and that “the most likely scenario, it is annual revaccinations.”

Advertisement

Trending